High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated

Carcinogenesis

Volumn 23, Issue 6, 2002, Pages 949-957

  Sohn, Taylor A ^a   Bansal, Ravi ^a   Su, Gloria H ^a   Murphy, Kathleen M ^a   Kern, Scott E ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; AMSACRINE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ARTEMISININ; CAMPTOTHECIN; CHLOROQUINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DABEQUINE; DNA TOPOISOMERASE; DOXORUBICIN; ETOPOSIDE; FLAVONOID; FLUOROURACIL; GEMCITABINE; HYDRALAZINE; MEPACRINE; METHOTREXATE; MITOMYCIN C; NIFEDIPINE; PACLITAXEL; PENTAMIDINE; PROTEIN P53; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOZOCIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ARTICLE; CARCINOGENICITY; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG STRUCTURE; ENVIRONMENTAL EXPOSURE; GENETIC ENGINEERING; GENOTOXICITY; HUMAN; HUMAN CELL; IONIZING RADIATION; MUTAGEN TESTING; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STABILITY; REPORTER GENE; STIMULUS RESPONSE;

EID: 0036317090     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/23.6.949     Document Type: Article

References (60)

1. p53 gene mutations occur in diverse human tumour types
2. p53 mutations in human cancers
3. p53, the cellular gatekeeper for growth and division
4. Genotoxic and non-genotoxic pathways of p53 induction
5. Suppression of human colorectal carcinoma cell growth by wild-type p53
6. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
7. DNA damage-induced activation of p53 by the checkpoint kinase Chk2
8. Caffeine inhibits the checkpoint kinase ATM
9. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase
10. Screening hCHK2 for mutations
11. Chk2/hCds1 functions as a DNA damage checkpoint in G (1) by stabilizing p53
12. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites
13. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures
14. ATR and ATRIP: Partners in checkpoint signaling
15. Defective G2 checkpoint function in cells from individuals with familial cancer syndromes
16. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro
17. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
18. Mdm2 promotes the rapid degradation of p53
19. Regulation of p53 stability by Mdm2
20. A quantitative analysis of the kinetics of the G (2) DNA damage checkpoint system
21. Identification of p53 as a sequence-specific DNA-binding protein
22. Definition of a consensus binding site for p53
23. A transcriptionally active DNA-binding site for human p53 protein complexes
24. Oncogenic forms of p53 inhibit p53-regulated gene expression
25. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine
26. ATR is a caffeine-sensitive, DNA-activated protein kinase with a substrate specificity distinct from DNA-PK
27. Two molecularly distinct g (2)/m checkpoints are induced by ionizing irradiation
28. Participation of p53 protein in the cellular response to DNA damage
29. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
30. p53 induction as a genotoxic test for twenty-five chemicals undergoing in vivo carcinogenicity testing
31. A new approach to identifying genotoxic carcinogens: p53 induction as an indicator of genotoxic damage
32. Identification of genotoxic stress in human cells by fluorescent monitoring of p53 expression
33. Requirement for p53 and p21 to sustain G2 arrest after DNA damage
34. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library
35. High-throughput drug screening of the DPC4 tumor-suppressor pathway in human pancreatic cancer cells
36. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
37. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions
38. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen
39. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy
40. Small molecule developmental screens reveal the logic and timing of vertebrate development
41. Synthesis and antiproliferative activity of some variously substituted acridine and azacridine derivatives
42. The potential of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide to circumvent three multidrug-resistance phenotypes in vitro
43. 9-substituted acridine derivatives with long half-life and potent antitumor activity: Synthesis and structure-activity relationships
44. [Possible carcinogenic activity of the Soviet antimalarial dabequin in a chronic experiment in animals.]
45. On the metabolism of quinoline and isoquinoline: Possible molecular basis for differences in biological activities
46. The chemotherapy of rodent malaria. XLIV. Studies on the mode of action of CM 6606, an indolo (3,2-c) quinoline N-oxide
47. Data quality in predictive toxicology: Reproducibility of rodent carcinogenicity experiments
48. Cellular events and the pattern of p53 protein expression following cyclophosphamide-initiated cell death in various organs of developing embryo
49. Expression of p53, Bcl-2 and Bax in Cd34+ cells recovering after chemotherapy
50. DNA strand breaks: The DNA template alterations that trigger p53-dependent DNA damage response pathways
51. Flavonoids as DNA topoisomerase antagonists and poisons: Structure-activity relationships
52. Role of plant polyphenols in genomic stability
53. Cell-cycle arrest at G2/M and growth inhibition by apigenin in human colon carcinoma cell lines
54. Increase in wild-type p53 stability and transactivational activity by the chemopreventive agent apigenin in keratinocytes
55. A pilot study on risk factors and p53 gene expression in colorectal cancer
56. In vivo and in vitro effects of hydralazine on cellular growth, differentiation and chromatin structure
57. Quinolone congeners as mammalian topoisomerase-II inhibitors
58. [Pharmacokinetics of the new antimalarial preparation dabequin studied in monkeys.]
59. [The Soviet antimalarial preparation dabequine studied for the presence of mutagenic activity.]
60. [Effectiveness of treatment with chloroquine, fansidar and dabequin of Plasmodium falciparum carriers, residing in a hyperendemic focus of malaria (the city of Bagamoyo, Northeastern Tanzania).]